Quarterly report pursuant to Section 13 or 15(d)

Restructuring Related Expenses

v3.23.2
Restructuring Related Expenses
6 Months Ended
Jun. 30, 2023
Restructuring And Related Activities [Abstract]  
Restructuring Related Expenses

NOTE 12 – RESTRUCTURING RELATED EXPENSES

On March 29, 2023, the Company implemented a strategic reprioritization and corresponding reduction in workforce, designed to focus on the clinical development programs for MT-6402, MT-8421 and MT-0169, and preclinical activities related to the Company’s collaboration with Bristol Myers Squibb (the “Restructuring”). The Restructuring reduced the Company’s workforce, ceased further development of the Company’s MT-5111 clinical development program, and refocused the majority of the Company’s pre-clinical efforts around activities related to the Bristol Myers Squibb collaboration. On June 16, 2023, the Company implemented an additional reduction in workforce, reducing the Company’s workforce by approximately 44%. For the three and six months ended June 30, 2023, the Company incurred zero and $0.3 million, respectively, in expenses related to the Restructuring, which is included in research and development and general and administrative expenses in the condensed consolidated statement of operations. The expenses related to the Restructuring related to severance pay and other related termination benefits. The

Company estimates that it will not incur any additional Restructuring related costs as of the time of issuance of these financial statements.

The following table summarizes the activity for the six months ended June 30, 2023 for expenses related to the Restructuring accruals, which are included in Accrued liabilities in the Company’s condensed consolidated balance sheets as of June 30, 2023 (in thousands):

Balance, December 31, 2022

    

$

Restructuring expenses

276

Cash payments

(276)

Balance, June 30, 2023

$